Jakob Felding

UNION Therapeutics
Hellerup, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Orismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis.

Orismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis.

Journal: Experimental dermatology

Published: January 21, 2025

Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis.

Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis.

Journal: Dermatology and therapy

Published: December 19, 2024

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS).

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS).

Journal: The British journal of dermatology

Published: September 18, 2024

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.

Journal: Dermatology and therapy

Published: August 18, 2023

Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.

Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 18, 2022

Pharmacology of orismilast, a potent and selective PDE4 inhibitor.

Pharmacology of orismilast, a potent and selective PDE4 inhibitor.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 18, 2022

Solid-phase synthesis and biological evaluation of piperazine-based novel bacterial topoisomerase inhibitors.

Solid-phase synthesis and biological evaluation of piperazine-based novel bacterial topoisomerase inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: October 05, 2021

Divergent synthesis of thapsigargin analogs.

Divergent synthesis of thapsigargin analogs.

Journal: Bioorganic & medicinal chemistry letters

Published: February 19, 2018

Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.

Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs.

Journal: ACS central science

Published: September 10, 2017

Scalable Synthesis of (-)-Thapsigargin.

Scalable Synthesis of (-)-Thapsigargin.

Journal: ACS central science

Published: October 19, 2016

Nineteen-step total synthesis of (+)-phorbol.

Nineteen-step total synthesis of (+)-phorbol.

Journal: Nature

Published: December 04, 2015

Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.

Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.

Journal: Future medicinal chemistry

Published: September 23, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026